Diabetic heart disease (DHD) is the primary cause of mortality in people with diabetes. A significant contributor to the development of DHD is the disruption of redox balance due to reactive oxygen species (ROS) overproduction resulting from sustained high glucose levels. Therapies specifically focusing on the suppression of ROS will hugely benefit patients with DHD.
Recent Advances:
In addition to the gold standard pharmacological therapies, the recent development of gene therapy provides an exciting avenue for developing new therapeutics to treat ROS-mediated DHD. In particular, microRNAs (miRNAs) are gaining interest due to their crucial role in several physiological and pathological processes, including DHD.
Critical Issues:
miRNAs have many targets and differential function depending on the environment. Therefore, a proper understanding of the function of miRNAs in specific cell types and cell states is required for the successful application of this technology. In the present review, we first provide an overview of the role of ROS in contributing to DHD and the currently available treatments. We then discuss the newer gene therapies with a specific focus on the role of miRNAs as the causative factors and therapeutic targets to combat ROS-mediated DHD.
Future Directions:
The future of miRNA therapeutics in tackling ROS-mediated DHD is dependent on a complete understanding of how miRNAs behave in different cells and environments. Future research should also aim to develop conditional miRNA therapeutic platforms capable of switching on and off in response to disruptions in the redox state. Antioxid. Redox Signal. 36, 608–630.
Get full access to this article
View all access options for this article.
References
1.
AabergeL, NordstrandK, DragsundM, SaatvedtK, EndresenK, GolfS, GeiranO, AbdelnoorM, and ForfangK. Transmyocardial revascularization with CO2 laser in patients with refractory angina pectoris: clinical results from The Norwegian Randomized Trial. J Am Coll Cardiol, 35: 1170–1177, 2000.
2.
Abd-AzizN, KamaruzmanNI, and PohCL. Development of microRNAs as potential therapeutics against cancer. J Oncol 2020; [Epub ahead of print]; DOI: 10.1155/2020/80297212020.
3.
Al-MuhtareshHA, SalemAH, and Al-KafajiG. Upregulation of circulating cardiomyocyte-enriched miR-1 and miR-133 associate with the risk of coronary artery disease in type 2 diabetes patients and serve as potential biomarkers. J Cardiovasc Transl Res, 12: 347–357, 2019.
4.
AlarcónCR, LeeH, GoodarziH, HalbergN, and TavazoieSF. N6-methyladenosine marks primary microRNAs for processing. Nature, 519: 482–485, 2015.
5.
AllesJ, FehlmannT, FischerU, BackesC, GalataV, MinetM, HartM, Abu-HalimaM, GrässerFA, LenhofH-P, KellerA, and MeeseE. An estimate of the total number of true human miRNAs. Nucleic Acids Res, 47: 3353–3364, 2019.
6.
AlpNJ, MussaS, KhooJ, CaiS, GuzikT, JeffersonA, GohN, RockettKA, and ChannonKM. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest, 112: 725–735, 2003.
7.
AmbrosV.The functions of animal microRNAs. Nature, 431: 350–355, 2004.
8.
AoyamaT, SouriM, UshikuboS, KamijoT, YamaguchiS, KelleyRI, RheadWJ, UetakeK, TanakaK, and HashimotoT. Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients. J Clin Invest, 95: 2465–2473, 1995.
9.
ArdeshirlarijaniE, Tabatabaei-MalazyO, MohseniS, QorbaniM, LarijaniB, and Baradar JaliliR. Effect of probiotics supplementation on glucose and oxidative stress in type 2 diabetes mellitus: a meta-analysis of randomized trials. Daru, 27: 827–837, 2019.
10.
AsbaghiO, ChoghakhoriR, and AbbasnezhadA. Effect of omega-3 and vitamin E co-supplementation on serum lipids concentrations in overweight patients with metabolic disorders: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr, 13: 2525–2531, 2019.
11.
AsmatU, AbadK, and IsmailK. Diabetes mellitus and oxidative stress-a concise review. Saudi Pharm J, 24: 547–553, 2016.
12.
BabiarzJE, RubyJG, WangY, BartelDP, and BlellochR. Mouse ES cells express endogenous shRNAs, siRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. Genes Dev, 22: 2773–2785, 2008.
13.
BansalP and AroraM. Small interfering RNAs and RNA therapeutics in cardiovascular diseases. Adv Exp Med Biol, 1229: 369–381, 2020.
14.
BartonM.Prevention and endothelial therapy of coronary artery disease. Curr Opin Pharmacol, 13: 226–241, 2013.
15.
Bellae PapannaraoJ, SchwenkeDO, ManningPJ, and KatareR. Upregulated miR-200c may increase the risk of obese individuals to severe COVID-19. medRxiv [Epub ahead of print]; DOI: 10.1101/2021.03.29.21254517, 2021.
16.
BensaadK, TsurutaA, SelakMA, VidalMNC, NakanoK, BartronsR, GottliebE, and VousdenKH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 126: 107–120, 2006.
17.
BernardoBC, GaoX-M, WinbanksCE, BoeyEJH, ThamYK, KiriazisH, GregorevicP, ObadS, KauppinenS, DuX-J, LinRCY, and McMullenJR. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A, 109: 17615–17620, 2012.
18.
BetteridgeDJ.What is oxidative stress?. Metabolism, 49: 3–8, 2000.
BudanovAV.Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling. Antioxid Redox Signal, 15: 1679–1690, 2011.
21.
BuggerH and AbelED. Mitochondria in the diabetic heart. Cardiovasc Res, 88: 229–240, 2010.
22.
BuggerH and AbelED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia, 57: 660–671, 2014.
23.
CaiB, MaW, BiC, YangF, ZhangL, HanZ, HuangQ, DingF, LiY, YanG, PanZ, YangB, and LuY. Long noncoding RNA H19 mediates melatonin inhibition of premature senescence of c-kit(+) cardiac progenitor cells by promoting miR-675. J Pineal Res, 61: 82–95, 2016.
24.
CannellIG, KongYW, and BushellM. How do microRNAs regulate gene expression?. Biochem Soc Trans, 36: 1224–1231, 2008.
25.
CasasAI, NogalesC, MuckeHAM, PetrainaA, CuadradoA, RojoAI, GhezziP, JaquetV, AugsburgerF, DufrasneF, SoubhyeJ, DeshwalS, Di SanteM, KaludercicN, Di LisaF, and SchmidtH. On the clinical pharmacology of reactive oxygen species. Pharmacol Rev, 72: 801–828, 2020.
26.
ChakrabortyC, SharmaAR, SharmaG, and LeeS-S. Therapeutic advances of miRNAs: a preclinical and clinical update. J Adv Res, 28: 127–138, 2021.
27.
ChanSY and LoscalzoJ. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle, 9: 1072–1083, 2010.
28.
ChenJ, KeS, ZhongL, WuJ, TsengA, MorpurgoB, GolovkoA, WangG, CaiJJ, MaX, LiD, and TianY. Long noncoding RNA MALAT1 regulates generation of reactive oxygen species and the insulin responses in male mice. Biochem Pharmacol, 152: 94–103, 2018.
29.
ChenJ-F, MandelEM, ThomsonJM, WuQ, CallisTE, HammondSM, ConlonFL, and WangD-Z. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet, 38: 228–233, 2006.
30.
ChiuY-L and RanaTM. siRNA function in RNAi: a chemical modification analysis. RNA, 9: 1034–1048, 2003.
31.
ChoNH, ShawJE, KarurangaS, HuangY, da Rocha FernandesJD, OhlroggeAW, and MalandaB. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract, 138: 271–281, 2018.
32.
CingolaniHE, PlastinoJA, EscuderoEM, MangalB, BrownJ, and PerezNG. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata study. J Card Fail, 12: 491–498, 2006.
33.
CohnR, ThakarK, LoweA, LadhaFA, PettinatoAM, RomanoR, MeredithE, ChenY-S, AtamanukK, HueyBD, and HinsonJT. A contraction stress model of hypertrophic cardiomyopathy due to sarcomere mutations. Stem Cell Rep, 12: 71–83, 2019.
34.
ColasP, CohenB, JessenT, GrishinaI, McCoyJ, and BrentR. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature, 380: 548–550, 1996.
35.
CotterFE, WatersJ, and CunninghamD. Human Bcl-2 antisense therapy for lymphomas. Biochim Biophys Acta, 1489: 97–106, 1999.
36.
D'AgostinoM, MartinoF, SilenoS, BarillaF, BejiS, MarchettiL, GangiFM, PersicoL, PicozzaM, MontaliA, MartinoE, ZanoniC, AvitabileD, ParrottoS, CapogrossiMC, and MagentaA. Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels: implication of a ZEB1-dependent mechanism. Clin Sci (Lond), 131: 2397–2408, 2017.
37.
D'OriaR, SchipaniR, LeonardiniA, NatalicchioA, PerriniS, CignarelliA, LaviolaL, and GiorginoF. The role of oxidative stress in cardiac disease: from physiological response to injury factor. Oxid Med Cell Longev 2020 [Epub ahead of print]; DOI: 10.1155/2020/5732956, 2020.
38.
DandamudiS, SlusserJ, MahoneyDW, RedfieldMM, RodehefferRJ, and ChenHH. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail, 20: 304–309, 2014.
39.
DeevR, PlaksaI, BozoI, MzhavanadzeN, SuchkovI, ChervyakovY, StaroverovI, KalininR, and IsaevA. Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication. Ther Adv Cardiovasc Dis, 12: 237–246, 2018.
40.
DengS, LiX, LiuS, ChenJ, LiM, ChewSY, LeongKW, and ChengD. Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects. Sci Adv, 6: eabb4005, 2020.
41.
DenliAM, TopsBBJ, PlasterkRHA, KettingRF, and HannonGJ. Processing of primary microRNAs by the microprocessor complex. Nature, 432: 231–235, 2004.
42.
DingC, QianC, HouS, LuJ, ZouQ, LiH, and HuangB. Exosomal miRNA-320a is released from hAMSCs and regulates SIRT4 to prevent reactive oxygen species generation in POI. Mol Ther Nucleic Acids, 21: 37–50, 2020.
43.
DludlaPV, NyambuyaTM, OrlandoP, SilvestriS, MxinwaV, MokgalaboniK, NkambuleBB, LouwJ, MullerCJF, and TianoL. The impact of coenzyme Q10 on metabolic and cardiovascular disease profiles in diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab, 3: e00118, 2020.
44.
DoreLC, AmigoJD, dos SantosCO, ZhangZ, GaiX, TobiasJW, YuD, KleinAM, DormanC, WuW, HardisonRC, PawBH, and WeissMJ. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A, 105: 3333–3338, 2008.
45.
Dos SantosJM, TewariS, and MendesRH. The role of oxidative stress in the development of diabetes mellitus and its complications. J Diabetes Res, 2019: 4189813, 2019.
46.
Doudna J (ed.). Genome Engineering with CRISP-Cas9: Birth of a Breakthrough Technology. iBiology Podcast. University of California, Berkeley, Howard Hughes Medical Institute, 2016.
47.
DuH, ZhaoY, YinZ, WangDW, and ChenC. The role of miR-320 in glucose and lipid metabolism disorder-associated diseases. Int J Biol Sci, 17: 402–416, 2021.
48.
DuenasA, ExpositoA, MunozMDM, de ManuelMJ, Camara-MoralesA, Serrano-OsorioF, Garcia-PadillaC, Hernandez-TorresF, DominguezJN, AranegaA, and FrancoD. MiR-195 enhances cardiomyogenic differentiation of the proepicardium/septum transversum by Smurf1 and Foxp1 modulation. Sci Rep, 10: 9334, 2020.
49.
DunlopM.Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int, 58: S3–S12, 2000.
50.
This reference has been deleted.
51.
EelenG, de ZeeuwP, SimonsM, and CarmelietP. Endothelial cell metabolism in normal and diseased vasculature. Circ Res, 116: 1231–1244, 2015.
52.
EinarsonTR, AcsA, LudwigC, and PantonUH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol, 17: 83, 2018.
53.
Emerging Risk FactorsCollaboration, SarwarN, GaoP, SeshasaiSRK, GobinR, KaptogeS, Di AngelantonioE, IngelssonE, LawlorDA, SelvinE, StampferM, StehouwerCDA, LewingtonS, PennellsL, ThompsonA, SattarN, WhiteIR, RayKK, and DaneshJ. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, 375: 2215–2222, 2010.
54.
FangY-C and YehC-H. Inhibition of miR-302 suppresses hypoxia-reoxygenation-induced H9c2 cardiomyocyte death by regulating Mcl-1 expression. Oxid Med Cell Longev, 2017: 7968905, 2017.
55.
FlavinRJ, SmythPC, LaiosA, O'TooleSA, BarrettC, FinnSP, RussellS, RingM, DenningKM, LiJ, AherneST, SammaraeDA, AzizNA, AlhadiA, SheppardBL, LaoK, SheilsOM, and O'LearyJJ. Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Mod Pathol, 22: 197–205, 2009.
56.
FoinquinosA, BatkaiS, GenschelC, ViereckJ, RumpS, GyöngyösiM, TraxlerD, RiesenhuberM, SpannbauerA, LukovicD, WeberN, ZlabingerK, HašimbegovićE, WinklerJ, FiedlerJ, DangwalS, FischerM, de la RocheJ, WojciechowskiD, KraftT, GaramvölgyiR, NeitzelS, ChatterjeeS, YinX, BärC, MayrM, XiaoK, and ThumT. Preclinical development of a miR-132 inhibitor for heart failure treatment. Nat Commun, 11: 633, 2020.
57.
Fomison-NurseI, SawEEL, GandhiS, MunasinghePE, Van HoutI, WilliamsMJA, GalvinI, BuntonR, DavisP, CameronV, and KatareR. Diabetes induces the activation of pro-ageing miR-34a in the heart, but has differential effects on cardiomyocytes and cardiac progenitor cells. Cell Death Differ, 25: 1336–1349, 2018.
58.
ForbesJM and CooperME. Mechanisms of diabetic complications. Physiol Rev, 93: 137–188, 2013.
59.
FriedmanRC, FarhKK, BurgeCB, and BartelDP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 19: 92–105, 2009.
GavinJR, 3rd, PetersonK, and Warren-BoultonE. Reducing cardiovascular disease risk in patients with type 2 diabetes: a message from the National Diabetes Education Program. Am Fam Physician, 68: 1569–1574, 2003.
63.
GongW, ZhuG, LiJ, and YangX. LncRNA MALAT1 promotes the apoptosis and oxidative stress of human lens epithelial cells via p38MAPK pathway in diabetic cataract. Diabetes Res Clin Pract, 144: 314–321, 2018.
64.
GouL, ZhaoL, SongW, WangL, LiuJ, ZhangH, HuangY, LauCW, YaoX, TianXY, WongWT, LuoJ-Y, and HuangY. Inhibition of miR-92a suppresses oxidative stress and improves endothelial function by upregulating heme oxygenase-1 in db/db mice. Antioxid Redox Signal, 28: 358–370, 2017.
65.
Gouni-BertholdI.The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia. Atheroscler Suppl, 30: 19–27, 2017.
66.
Granados-RiveronJT and Aquino-JarquinG. CRISPR–Cas13 precision transcriptome engineering in cancer. Cancer Res, 78: 4107–4113, 2018.
67.
GrecoS, FasanaroP, CastelvecchioS, D'AlessandraY, ArcelliD, Di DonatoM, MalavazosA, CapogrossiMC, MenicantiL, and MartelliF. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes, 61: 1633–1641, 2012.
68.
This reference has been deleted.
69.
GuoX, GuoS, PanL, RuanL, GuY, and LaiJ. Anti-microRNA-21/221 and microRNA-199a transfected by ultrasound microbubbles induces the apoptosis of human hepatoma HepG2 cells. Oncol Lett, 13: 3669–3675, 2017.
70.
HanJ, LeeY, YeomK-H, KimY-K, JinH, and KimVN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev, 18: 3016–3027, 2004.
71.
HavensMA and HastingsML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res, 44: 6549–6563, 2016.
72.
HayashitaY, OsadaH, TatematsuY, YamadaH, YanagisawaK, TomidaS, YatabeY, KawaharaK, SekidoY, and TakahashiT. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res, 65: 9628–9632, 2005.
73.
HeB, XiaoJ, RenAJ, ZhangYF, ZhangH, ChenM, XieB, GaoXG, and WangYW. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J Biomed Sci, 18: 22, 2011.
HingtgenSD, TianX, YangJ, DunlaySM, PeekAS, WuY, SharmaRV, EngelhardtJF, and DavissonRL. Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiol Genomics, 26: 180–191, 2006.
76.
HoFM, LinWW, ChenBC, ChaoCM, YangCR, LinLY, LaiCC, LiuSH, and LiauCS. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal, 18: 391–399, 2006.
77.
HongDS, KangY-K, BrennerAJ, SachdevJC, EjadiS, BoradMJ, KimT-Y, LimHY, ParkK, BecerraC, BaderAG, StoudemireJ, SmithS, KimS, and BegMS. MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: final dose-escalation results from a first-in-human phase I trial of microRNA therapy. J Clin Oncol, 34: 2508, 2016.
78.
HuB, ZhongL, WengY, PengL, HuangY, ZhaoY, and LiangX-J. Therapeutic siRNA: state of the art. Signal Transduct Target Ther, 5: 101, 2020.
79.
HuY, LiuS, and ZhuBM. CRISPR/Cas9-induced loss of Keap1 enhances anti-oxidation in rat adipose-derived mesenchymal stem cells. Front Neurol, 10: 1311, 2019.
80.
HuangX, LvJ, LiY, MaoS, LiZ, JingZ, SunY, ZhangX, ShenS, WangX, DiM, GeJ, HuangX, ZuoE, and ChiT. Programmable C-to-U RNA editing using the human APOBEC3A deaminase. EMBO J, 39: e104741, 2020.
81.
IkedaS, HeA, KongSW, LuJ, BejarR, BodyakN, LeeK-H, MaQ, KangPM, GolubTR, and PuWT. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol, 29: 2193–2204, 2009.
82.
IsmailN, AbdullahN, Abdul MuradNA, JamalR, and SulaimanSA. Long non-coding RNAs (lncRNAs) in cardiovascular disease complication of type 2 diabetes. Diagnostics (Basel), 11: 145, 2021.
83.
ItahanaY, HanR, BarbierS, LeiZ, RozenS, and ItahanaK. The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. Oncogene, 34: 1799–1810, 2015.
84.
KangJ, JeongMG, OhS, JangEJ, KimHK, and HwangES. A FoxO1-dependent, but NRF2-independent induction of heme oxygenase-1 during muscle atrophy. FEBS Lett, 588: 79–85, 2014.
85.
KarolinaDS, ArmugamA, TavintharanS, WongMT, LimSC, SumCF, and JeyaseelanK. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One, 6: e22839, 2011.
86.
KawamataT and TomariY. Making RISC. Trends Biochem Sci, 35: 368–376, 2010.
87.
KayamaY, RaazU, JaggerA, AdamM, SchellingerIN, SakamotoM, SuzukiH, ToyamaK, SpinJM, and TsaoPS. Diabetic cardiovascular disease induced by oxidative stress. Int J Mol Sci, 16: 25234–25263, 2015.
88.
KazemiB, AkbarzadehF, SafaeiN, YaghoubiA, ShadvarK, and GhasemiK. Prophylactic high-dose oral-N-acetylcysteine does not prevent atrial fibrillation after heart surgery. Pacing Clin Electrophysiol, 36: 1211–1219, 2013.
89.
KimJ, ParkH, SaravanakumarG, and KimWJ. Polymer/aptamer-integrated gold nanoconstruct suppresses the inflammatory process by scavenging ROS and capturing pro-inflammatory cytokine TNF-alpha. ACS Appl Mater Interfaces, 13: 9390–9401, 2021.
90.
KimJH, ParkSG, SongSY, KimJK, and SungJH. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Cell Death Dis, 4: e588, 2013.
91.
KimJY, ShinKK, LeeAL, KimYS, ParkHJ, ParkYK, BaeYC, and JungJS. MicroRNA-302 induces proliferation and inhibits oxidant-induced cell death in human adipose tissue-derived mesenchymal stem cells. Cell Death Dis, 5: e1385, 2014.
92.
Kumar KulabhusanP, HussainB, and YüceM. Current perspectives on aptamers as diagnostic tools and therapeutic agents. Pharmaceutics, 12: 646, 2020.
93.
KuraB, Szeiffova BacovaB, KalocayovaB, SykoraM, and SlezakJ. Oxidative stress-responsive microRNAs in heart injury. Int J Mol Sci, 21: 358, 2020.
94.
KushawahG, Hernandez-HuertasL, Abugattas-Nuñez Del PradoJ, Martinez-MoralesJR, DeVoreML, HassanH, Moreno-SanchezI, Tomas-GallardoL, Diaz-MoscosoA, MongesDE, GuelfoJR, TheuneWC, BrannanEO, WangW, CorbinTJ, MoranAM, Sánchez AlvaradoA, Málaga-TrilloE, TakacsCM, BazziniAA, and Moreno-MateosMA. CRISPR-Cas13d induces efficient mRNA knockdown in animal embryos. Dev Cell, 54: 805–817.e7, 2020.
95.
LainaA, GatsiouA, GeorgiopoulosG, StamatelopoulosK, and StellosK. RNA therapeutics in cardiovascular precision medicine. Front Physiol, 9: 953, 2018.
96.
LeeRC, FeinbaumRL, and AmbrosV. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75: 843–854, 1993.
97.
LeonBM and MaddoxTM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes, 6: 1246–1258, 2015.
98.
LeopoldJA.Antioxidants and coronary artery disease: from pathophysiology to preventive therapy. Coron Artery Dis, 26: 176–183, 2015.
99.
LiF, PeiL, HuangG, and YeH. Influence of omega-3 fatty acid and vitamin co-supplementation on metabolic status in gestational diabetes: a meta-analysis of randomized controlled studies. Eur J Obstet Gynecol Reprod Biol, 247: 191–197, 2020.
100.
LiN and ZhouH. SGLT2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy. Drug Des Devel Ther, 14: 4775–4788, 2020.
101.
LiT, ZhangX, JiangK, LiuJ, and LiuZ. Dural effects of oxidative stress on cardiomyogenesis via Gata4 transcription and protein ubiquitination. Cell Death Dis, 9: 246, 2018.
102.
LiangY-Z, DongJ, ZhangJ, WangS, HeY, and YanY-X. Identification of neuroendocrine stress response-related circulating microRNAs as biomarkers for type 2 diabetes mellitus and insulin resistance. Front Endocrinol, 9: 132, 2018.
103.
LinN, LiXY, ZhangHM, YangZ, and SuQ. microRNA-199a-5p mediates high glucose-induced reactive oxygen species production and apoptosis in INS-1 pancreatic beta-cells by targeting SIRT1. Eur Rev Med Pharmacol Sci, 21: 1091–1098, 2017.
104.
LinX, XuY, PanX, XuJ, DingY, SunX, SongX, RenY, and ShanP-F. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep, 10: 14790, 2020.
105.
LinZ, MurtazaI, WangK, JiaoJ, GaoJ, and LiPF. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A, 106: 12103–12108, 2009.
106.
LiuA, SunY, and YuB. MicroRNA-208a correlates apoptosis and oxidative stress induced by H2O2 through protein tyrosine kinase/phosphatase balance in cardiomyocytes. Int Heart J, 59: 829–836, 2018.
107.
LiuJ, ZhangC, HuW, and FengZ. Tumor suppressor p53 and metabolism. J Mol Cell Biol, 11: 284–292, 2019.
108.
LongB, GanT-Y, ZhangR-C, and ZhangY-H. miR-23a regulates cardiomyocyte apoptosis by targeting manganese superoxide dismutase. Mol Cells, 40: 542–549, 2017.
109.
LopaschukGD, UssherJR, FolmesCD, JaswalJS, and StanleyWC. Myocardial fatty acid metabolism in health and disease. Physiol Rev, 90: 207–258, 2010.
110.
LuJ, DongH, LinL, WangQ, HuangL, and TanJ. miRNA-302 facilitates reprogramming of human adult hepatocytes into pancreatic islets-like cells in combination with a chemical defined media. Biochem Biophys Res Commun, 453: 405–410, 2014.
111.
LushaE, JiangH, and LuZ. MicroRNA-144 attenuates cardiac ischemia/reperfusion injury by targeting FOXO1. Exp Ther Med, 17: 2152–2160, 2019
112.
MaaloufRM, EidAA, GorinYC, BlockK, EscobarGP, BaileyS, and AbboudHE. Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes. Am J Physiol Cell Physiol, 302: C597–C604, 2012.
113.
MagentaA, CencioniC, FasanaroP, ZaccagniniG, GrecoS, Sarra-FerrarisG, AntoniniA, MartelliF, and CapogrossiMC. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ, 18: 1628–1639, 2011.
114.
MagentaA, GrecoS, CapogrossiMC, GaetanoC, and MartelliF. Nitric oxide, oxidative stress, and p66Shc interplay in diabetic endothelial dysfunction. Biomed Res Int, 2014: 193095, 2014.
115.
MahalZ, FujikawaK, MatsuoH, ZahidHM, KoikeM, MisumiM, KanekoT, MashimoT, OharaH, and NabikaT. Effects of the Prdx2 depletion on blood pressure and life span in spontaneously hypertensive rats. Hypertens Res, 42: 610–617, 2019.
116.
MarcheseFP, RaimondiI, and HuarteM. The multidimensional mechanisms of long noncoding RNA function. Genome Biol, 18: 206, 2017.
117.
MartínezMS, GarcíaA, LuzardoE, Chávez-CastilloM, OlivarLC, SalazarJ, VelascoM, QuinteroJJR, and BermúdezV. Energetic metabolism in cardiomyocytes: molecular basis of heart ischemia and arrhythmogenesis. Vessel Plus, 1: 130–141, 2017.
118.
MerckenEM, MitchellSJ, Martin-MontalvoA, MinorRK, AlmeidaM, GomesAP, Scheibye-KnudsenM, PalaciosHH, LicataJJ, ZhangY, BeckerKG, KhraiweshH, Gonzalez-ReyesJA, VillalbaJM, BaurJA, ElliottP, WestphalC, VlasukGP, EllisJL, SinclairDA, BernierM, and de CaboR. SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell, 13: 787–796, 2014.
119.
MiricDJ, KisicBM, Filipovic-DanicS, GrbicR, DragojevicI, MiricMB, and Puhalo-SladojeD. Xanthine oxidase activity in type 2 diabetes mellitus patients with and without diabetic peripheral neuropathy. J Diabetes Res, 2016: 4370490, 2016.
120.
MittlerR.ROS are good. Trends Plant Sci, 22: 11–19, 2017.
121.
MontgomeryRL, HullingerTG, SemusHM, DickinsonBA, SetoAG, LynchJM, StackC, LatimerPA, OlsonEN, and RooijEV. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation, 124: 1537–1547, 2011.
122.
MorisD, SpartalisM, SpartalisE, KarachaliouG-S, KaraolanisGI, TsourouflisG, TsilimigrasDI, TzatzakiE, and TheocharisS. The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox. Ann Transl Med, 5: 326, 2017.
123.
MutharasanRK, NagpalV, IchikawaY, and ArdehaliH. microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol, 301: H1519–H1530, 2011.
124.
MyungS-K, JuW, ChoB, OhS-W, ParkSM, KooB-K, and ParkB-J. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ, 346: f10, 2013.
125.
NaeemM, MajeedS, HoqueMZ, and AhmadI. Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing. Cells, 9:1608, 2020.
126.
NakamuraH, MatobaS, Iwai-KanaiE, KimataM, HoshinoA, NakaokaM, KatamuraM, OkawaY, AriyoshiM, MitaY, IkedaK, OkigakiM, AdachiS, TanakaH, TakamatsuT, and MatsubaraH. p53 promotes cardiac dysfunction in diabetic mellitus caused by excessive mitochondrial respiration-mediated reactive oxygen species generation and lipid accumulation. Circ Heart Fail, 5: 106–115, 2012.
127.
NimjeeSM, WhiteRR, BeckerRC, and SullengerBA. Aptamers as therapeutics. Annu Rev Pharmacol Toxicol, 57: 61–79, 2017.
128.
O'BrienJ, HayderH, ZayedY, and PengC. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne), 9: 402, 2018.
129.
OkadaC, YamashitaE, LeeSJ, ShibataS, KatahiraJ, NakagawaA, YonedaY, and TsukiharaT. A high-resolution structure of the pre-microRNA nuclear export machinery. Science, 326: 1275–1279, 2009.
130.
PanthN, PaudelKR, and ParajuliK. Reactive oxygen species: a key hallmark of cardiovascular disease. Adv Med, 2016: 9152732, 2016.
PaulS, AliA, and KatareR. Molecular complexities underlying the vascular complications of diabetes mellitus – a comprehensive review. J Diabetes Complications, 34: 107613, 2020.
133.
PeoplesJN, SarafA, GhazalN, PhamTT, and KwongJQ. Mitochondrial dysfunction and oxidative stress in heart disease. Exp Mol Med, 51: 1–13, 2019.
134.
PrasadKMR, XuY, YangZ, ActonST, and FrenchBA. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. Gene Ther, 18: 43–52, 2011.
135.
PurohitPK, EdwardsR, TokatlidisK, and SainiN. MiR-195 regulates mitochondrial function by targeting mitofusin-2 in breast cancer cells. RNA Biol, 16: 918–929, 2019.
136.
QadirMMF, KleinD, Alvarez-CubelaS, Dominguez-BendalaJ, and PastoriRL. The role of microRNAs in diabetes-related oxidative stress. Int J Mol Sci, 20: 5423, 2019.
137.
QuijanoC, TrujilloM, CastroL, and TrostchanskyA. Interplay between oxidant species and energy metabolism. Redox Biol, 8: 28–42, 2016.
138.
RamalingamL, MenikdiwelaK, LeMieuxM, DufourJM, KaurG, KalupahanaN, and Moustaid-MoussaN. The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance. Biochim Biophys Acta Mol Basis Dis, 1863: 1106–1114, 2017.
139.
RanaS, DattaK, ReddyTL, ChatterjeeE, SenP, Pal-BhadraM, BhadraU, PramanikA, PramanikP, Chawla-SarkarM, and SarkarS. A spatio-temporal cardiomyocyte targeted vector system for efficient delivery of therapeutic payloads to regress cardiac hypertrophy abating bystander effect. J Control Release, 200: 167–178, 2015.
140.
RaoPK, KumarRM, FarkhondehM, BaskervilleS, and LodishHF. Myogenic factors that regulate expression of muscle-specific microRNAs. Proc Natl Acad Sci U S A, 103: 8721–8726, 2006.
141.
RaoPK, ToyamaY, ChiangHR, GuptaS, BauerM, MedvidR, ReinhardtF, LiaoR, KriegerM, JaenischR, LodishHF, and BlellochR. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res, 105: 585–594, 2009.
142.
RawalS, NageshPT, CoffeyS, Van HoutI, GalvinIF, BuntonRW, DavisP, WilliamsMJA, and KatareR. Early dysregulation of cardiac-specific microRNA-208a is linked to maladaptive cardiac remodelling in diabetic myocardium. Cardiovasc Diabetol, 18: 13, 2019.
143.
RayKK, WrightRS, KallendD, KoenigW, LeiterLA, RaalFJ, BischJA, RichardsonT, JarosM, WijngaardPLJ, KasteleinJJP,
ORION-10, and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med, 382: 1507–1519, 2020.
144.
RodriguesJV and GomesCM. Mechanism of superoxide and hydrogen peroxide generation by human electron-transfer flavoprotein and pathological variants. Free Radic Biol Med, 53: 12–19, 2012.
145.
RossoA, BalsamoA, GambinoR, DentelliP, FalcioniR, CassaderM, PegoraroL, PaganoG, and BrizziMF. p53 mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes. J Biol Chem, 281: 4339–4347, 2006.
146.
RubyJG, JanCH, and BartelDP. Intronic microRNA precursors that bypass Drosha processing. Nature, 448: 83–86, 2007.
147.
SaeediP, SalpeaP, KarurangaS, PetersohnI, MalandaB, GreggEW, UnwinN, WildSH, and WilliamsR. Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract, 162: 108086, 2020.
148.
SawEL, PearsonJT, SchwenkeDO, MunasinghePE, TsuchimochiH, RawalS, CoffeyS, DavisP, BuntonR, Van HoutI, KaiY, WilliamsMJA, KakinumaY, FroniusM, and KatareR. Activation of the cardiac non-neuronal cholinergic system prevents the development of diabetes-associated cardiovascular complications. Cardiovasc Diabetol, 20: 50, 2021.
149.
SenonerT and DichtlW. Oxidative stress in cardiovascular diseases: still a therapeutic target?. Nutrients, 11: 2090, 2019.
150.
ShahMS and BrownleeM. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res, 118: 1808–1829, 2016.
151.
ShahzadMM, MangalaLS, HanHD, LuC, Bottsford-MillerJ, NishimuraM, MoraEM, LeeJW, StoneRL, PecotCV, ThanapprapasrD, RohJW, GaurP, NairMP, ParkYY, SabnisN, DeaversMT, LeeJS, EllisLM, Lopez-BeresteinG, McConathyWJ, ProkaiL, LackoAG, and SoodAK. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia, 13: 309–319, 2011.
152.
SheetzMJ and KingGL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA, 288: 2579–2588, 2002.
153.
ShenW, LuY, HuJ, LeH, YuW, XuW, YuW, and ZhengJ. Mechanism of miR-320 in regulating biological characteristics of ischemic cerebral neuron by mediating Nox2/ROS pathway. J Mol Neurosci, 70: 449–457, 2020.
154.
SimabucoFM, MoraleMG, PavanICB, MorelliAP, SilvaFR, and TamuraRE. p53 and metabolism: from mechanism to therapeutics. Oncotarget, 9: 23780–23823, 2018.
155.
SimmonsRA. Chapter 43: Cell glucose transport and glucose handling during fetal and neonatal development. In: Fetal and Neonatal Physiology (Fifth Edition), edited by Polin RA, Abman SH, Rowitch DH, Benitz WE, and Fox WW. Elsevier, 2017, pp. 428–435.e3.
156.
SotokawauchiA, NakamuraN, MatsuiT, HigashimotoY, and YamagishiSI. Glyceraldehyde-derived pyridinium evokes renal tubular cell damage via RAGE interaction. Int J Mol Sci, 21: 2604, 2020.
157.
SpeijerD, ManjeriGR, and SzklarczykR. How to deal with oxygen radicals stemming from mitochondrial fatty acid oxidation. Philos Trans R Soc Lond B Biol Sci, 369: 20130446, 2014.
158.
SrinounK, SathirapongsasutiN, PaiboonsukwongK, SretrirutchaiS, WongchanchailertM, and FucharoenS. miR-144 regulates oxidative stress tolerance of thalassemic erythroid cell via targeting NRF2. Ann Hematol, 98: 2045–2052, 2019.
159.
StrumJC, JohnsonJH, WardJ, XieH, FeildJ, HesterA, AlfordA, and WatersKM. MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1. Mol Endocrinol, 23: 1876–1884, 2009.
160.
SubramaniamA, JonesWK, GulickJ, WertS, NeumannJ, and RobbinsJ. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem, 266: 24613–24620, 1991.
161.
SudaH, MurakamiA, KagaT, TomiokaH, and MorishitaR. Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther, 12: 1145–1156, 2014.
162.
SunHJ, HouB, WangX, ZhuXX, LiKX, and QiuLY. Endothelial dysfunction and cardiometabolic diseases: role of long non-coding RNAs. Life Sci, 167: 6–11, 2016.
163.
SunW, JiW, HallJM, HuQ, WangC, BeiselCL, and GuZ. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew Chem Int Ed Engl, 54: 12029–12033, 2015.
164.
TianL, ChenM, HeQ, YanQ, and ZhaiC. MicroRNA‑199a‑5p suppresses cell proliferation, migration and invasion by targeting ITGA3 in colorectal cancer. Mol Med Rep, 22: 2307–2317, 2020.
165.
TianY, LiuY, WangT, ZhouN, KongJ, ChenL, SnitowM, MorleyM, LiD, PetrenkoN, ZhouS, LuM, GaoE, KochWJ, StewartKM, and MorriseyEE. A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice. Sci Transl Med, 7: 279ra38, 2015.
166.
This reference has been deleted.
167.
TianZQ, JiangH, and LuZB. MiR-320 regulates cardiomyocyte apoptosis induced by ischemia-reperfusion injury by targeting AKIP1. Cell Mol Biol Lett, 23: 41, 2018.
168.
TomarRS, MattaH, and ChaudharyPM. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene, 22: 5712–5715, 2003.
169.
TossiosP, BlochW, HuebnerA, RajiMR, DodosF, KlassO, SuedkampM, KasperSM, HellmichM, and MehlhornU. N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: results of a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg, 126: 1513–1520, 2003.
170.
TsutsuiH, KinugawaS, and MatsushimaS. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol, 301: H2181–H2190, 2011.
171.
UcarA, GuptaSK, FiedlerJ, ErikciE, KardasinskiM, BatkaiS, DangwalS, KumarswamyR, BangC, HolzmannA, RemkeJ, CaprioM, JentzschC, EngelhardtS, GeisendorfS, GlasC, HofmannTG, NesslingM, RichterK, SchifferM, CarrierL, NappLC, BauersachsJ, ChowdhuryK, and ThumT. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun, 3: 1078, 2012.
172.
VaidyaV, GanganN, and SheehanJ. Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review. Expert Rev Pharmacoecon Outcomes Res, 15: 487–497, 2015.
173.
van der PolA, van GilstWH, VoorsAA, and van der MeerP. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail, 21: 425–435, 2019.
174.
WanA and RodriguesB. Endothelial cell-cardiomyocyte crosstalk in diabetic cardiomyopathy. Cardiovasc Res, 111: 172–183, 2016.
175.
WangL, YuanY, LiJ, RenH, CaiQ, ChenX, LiangH, ShanH, FuZD, GaoX, LvY, YangB, and ZhangY. MicroRNA-1 aggravates cardiac oxidative stress by post-transcriptional modification of the antioxidant network. Cell Stress Chaperones, 20: 411–420, 2015.
176.
WangX, ShenC, ZhuJ, ShenG, LiZ, and DongJ. Long noncoding RNAs in the regulation of oxidative stress. Oxid Med Cell Longev, 2019: 1318795, 2019.
177.
WangX, ZhuH, ZhangX, LiuY, ChenJ, MedvedovicM, LiH, WeissMJ, RenX, and FanGC. Loss of the miR-144/451 cluster impairs ischaemic preconditioning-mediated cardioprotection by targeting Rac-1. Cardiovasc Res, 94: 379–390, 2012.
178.
WasH, DulakJ, and JozkowiczA. Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets, 11: 1551–1570, 2010.
179.
WightmanB, HaI, and RuvkunG. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 75: 855–862, 1993.
180.
WrightEJr., Scism-BaconJL, and GlassLC.Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract, 60: 308–314, 2006.
181.
WuF, WangF, YangQ, ZhangY, CaiK, LiuL, LiS, ZhengY, ZhangJ, GuiY, WangY, WangX, GuiY, and LiQ. Upregulation of miRNA-23a-3p rescues high glucose-induced cell apoptosis and proliferation inhibition in cardiomyocytes. In Vitro Cell Dev Biol Anim, 56: 866–877, 2020.
182.
WuM-R, NissimL, StuppD, PeryE, Binder-NissimA, WeisingerK, EnghuusC, PalaciosSR, HumphreyM, ZhangZ, Maria NovoaE, KellisM, WeissR, RabkinSD, TabachY, and LuTK. A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS). Nat Commun, 10: 2880, 2019.
183.
XieM, LiM, VilborgA, LeeN, ShuM-D, YartsevaV, ŠestanN, and Steitz JoanA. Mammalian 5′-capped microRNA precursors that generate a single microRNA. Cell, 155: 1568–1580, 2013.
184.
XiongL, ZengY, TangR-Q, AlperHS, BaiF-W, and ZhaoX-Q. Condition-specific promoter activities in Saccharomyces cerevisiae. Microb Cell Fact, 17: 58, 2018.
XuY, OsborneBW, and StantonRC. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol, 289: F1040–F1047, 2005.
187.
YangJ-S, MaurinT, RobineN, RasmussenKD, JeffreyKL, ChandwaniR, PapapetrouEP, SadelainM, O'CarrollD, and LaiEC. Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci U S A, 107: 15163–15168, 2010.
188.
YaoR-W, WangY, and ChenL-L. Cellular functions of long noncoding RNAs. Nat Cell Biol, 21: 542–551, 2019.
189.
YodaM, KawamataT, ParooZ, YeX, IwasakiS, LiuQ, and TomariY. ATP-dependent human RISC assembly pathways. Nat Struct Mol Biol, 17: 17–23, 2010.
190.
YuB, TaiHC, XueW, LeeLJ, and LeeRJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol, 27: 286–298, 2010.
191.
YuanT, YangT, ChenH, FuD, HuY, WangJ, YuanQ, YuH, XuW, and XieX. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol, 20: 247–260, 2019.
192.
ZhangH, KolbFA, JaskiewiczL, WesthofE, and FilipowiczW. Single processing center models for human dicer and bacterial RNase III. Cell, 118: 57–68, 2004.
193.
ZhangH, LiuJ, QuD, WangL, LuoJY, LauCW, LiuP, GaoZ, and TipoeGL, LeeHK, NgCF, MaRC, YaoX, HuangY. Inhibition of miR-200c restores endothelial function in diabetic mice through suppression of COX-2. Diabetes, 65: 1196–1207, 2016.
194.
ZhangL, LiaoY, and TangL. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res, 38: 53, 2019.
195.
ZhangL, SunY, FeiM, TanC, WuJ, ZhengJ, TangJ, SunW, LvZ, BaoJ, XuQ, and YuH. Disruption of chaperone-mediated autophagy-dependent degradation of MEF2A by oxidative stress-induced lysosome destabilization. Autophagy, 10: 1015–1035, 2014.
196.
ZhangL, ZhouM, WangY, HuangW, QinG, WeintraubNL, and TangY. miR-92a inhibits vascular smooth muscle cell apoptosis: role of the MKK4-JNK pathway. Apoptosis, 19: 975–983, 2014.
197.
ZhangY, LiY, HuangX, ZhangF, TangL, XuS, LiuY, TongN, and MinW. Systemic delivery of siRNA specific for silencing TLR4 gene expression reduces diabetic cardiomyopathy in a mouse model of streptozotocin-induced type 1 diabetes. Diabetes Ther, 11: 1161–1173, 2020.
198.
ZhaoR-Z, JiangS, ZhangL, and YuZ-B. Mitochondrial electron transport chain, ROS generation and uncoupling (review). Int J Mol Med, 44: 3–15, 2019.
199.
ZhengD, MaJ, YuY, LiM, NiR, WangG, ChenR, LiJ, FanG-C, LacefieldJC, and PengT. Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice. Diabetologia, 58: 1949–1958, 2015.
